Addressing bottlenecks in Lassa fever treatment: overcoming the ribavirin parenteral formulation challenge
Abstract Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200 mg/ml ampoule dosing o...
Published in: | Tropical Medicine and Health |
---|---|
Main Authors: | , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
BMC
2024
|
Subjects: | |
Online Access: | https://doi.org/10.1186/s41182-024-00609-0 https://doaj.org/article/59eff9db5ae74e70b7ea7134042a8695 |
Summary: | Abstract Ribavirin ampoule formulation remains a major challenge in managing Lassa fever disease. Lassa fever is an endemic viral hemorrhagic fever in the West Africa subregion, which has high-dose ribavirin as the standard of care. The high-dose therapy required makes the 200 mg/ml ampoule dosing of ribavirin a daunting task to administer, especially during disease outbreaks. This commentary highlights the challenges and makes a passionate call for vial dosage adjustment to fit the high-dose requirement of Lassa fever disease. |
---|